SCHEMBL9609812

SCHEMBL9609812

Cc1cc(Oc2ccc(N)c3ccccc23)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.47
EP300 Q09472 1/20 0.46
KAT8 Q9H7Z6 1/20 0.46
GAA P10253 2/20 0.39
ALDH1A1 P00352 1/20 0.39
NCF1 P14598 2/20 0.38
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
RCE1 Q9Y256 1/20 0.37
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
KDR P35968 1/20 0.34
UHRF1 Q96T88 1/20 0.34
TLR4 O00206 1/20 0.34
CYP2D6 P10635 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535725 0.85 IDO1 (0.46) IDO1EP300KAT8GAANCF1
SCHEMBL535774 0.82 IDO1 (0.44) IDO1EP300KAT8GAAALDH1A1
SCHEMBL20663706 0.82 IDO1 (0.44) IDO1EP300KAT8KDR
SCHEMBL17659975 0.80 MAPK14 (0.37) PDGFRBPDGFRA
SCHEMBL9609811 0.80 CHEK1 (0.38) EP300KAT8GAAALDH1A1PDGFRB
SCHEMBL6545883 0.79 IDO1 (0.44) IDO1EP300KAT8ALDH1A1PDGFRA
SCHEMBL16829073 0.79 MAPK14 (0.50) KDR
SCHEMBL5257415 0.78 IDO1 (0.52) IDO1EP300KAT8GAAALDH1A1
SCHEMBL13331029 0.78 GCK (0.49)
SCHEMBL15517417 0.77 SRC (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242960-B2 P38MAP kinase inhibitors Respivert, Ltd. (GB) 2016-01-26 US disclosed
US-20140228410-A1 P38MAP KINASE INHIBITORS RESPIVERT LTD. (GB) 2014-08-14 US disclosed
US-8642773-B2 P38MAP kinase inhibitor RESPIVERT LTD. (GB) 2014-02-04 US disclosed
US-20120136031-A1 P38MAP KINASE INHIBITOR RESPIVERT LTD. (GB) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228410-A1 P38MAP KINASE INHIBITORS MAPK1, MAP3K1, MAP3K11 IDO1 2059/4885EP300 1520/4885KAT8 1438/4885
US-20120136031-A1 P38MAP KINASE INHIBITOR MAPK1, MAP3K1, MAP3K11 IDO1 2120/4885EP300 1524/4885KAT8 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.